|
| Hi %%Firstname%%, |
|
| According to recent FDA guidance, “all drugs, including drugs intended for non-CNS indications, should be evaluated for adverse effects on the CNS” 1. Join us for this webinar to learn efficient and effective methods of meeting requirements for cognitive safety when developing new therapeutic compounds. |
|
| Hosted by Cambridge Cognition, the online event will be held on Wednesday 5th June at 11 a.m. EDT. Simply register to secure your place, and sign in remotely on the day. |
|
| Register for webinar |
|
| The webinar will discuss clinical trials that have benefitted from the computerized delivery of sensitive cognitive assessments to: |
|
| • |
Successfully navigate regulatory requirements for cognitive safety |
| • |
Facilitate early decision-making by generating accurate cognitive safety profiles |
| • |
Deliver differentiating label claims in an increasingly competitive market |
|
|
| If you are interested in the webinar, but unable to join us live, please register in the same way to access the recording. |
|
| I look forward to receiving your questions and discussing this important topic with you. |
|
Best wishes,
Kenton
Kenton Zavitz, PhD
Director of Clinical Affairs
Cambridge Cognition
Office: +44 (0)1223 810700
Email: info@camcog.com
Neuroscience technology
www.cambridgecognition.com |
|
